Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome

Cited by (1,016)

Items 301–400 of 1,016

1. Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk
   Julio Rosenstock, Vlado Perkovic, John Hunter Alexander, Mark Emmanuel Cooper, Nikolaus Marx, Michael J. Pencina, Robert D. Toto, Christoph Wanner, Bernard Zinman, David Baanstra et al. · 2018 · Cardiovascular Diabetology
2. Network Meta-Analysis of Novel Glucose-Lowering Drugs on Risk of Acute Kidney Injury
   Min Zhao, Shusen Sun, Zhenguang Huang, Tiansheng Wang, Huilin Tang · 2020 · Clinical Journal of the American Society of Nephrology
3. Transition metal complexes of imidazole derived Schiff bases: Antioxidant/anti-inflammatory/antimicrobial/enzyme inhibition and cytotoxicity properties
   G. Anjali Krishna, T.M. Dhanya, Angamaly Antony Shanty, Kozhiparambil Gopalan Raghu, Pezholil Mohanan · 2022 · Journal of Molecular Structure
4. Benefits of GLP-1 (Glucagon-Like Peptide 1) Receptor Agonists for Stroke Reduction in Type 2 Diabetes: A Call to Action for Neurologists
   Goldenberg, Ronald M., Cheng, Alice Y.Y., Fitzpatrick, Tess, Gilbert, Jeremy D., Verma, Subodh, Hopyan, Julia J. · 2022 · Stroke
5. Mechanistic insights regarding the role of SGLT2 inhibitors and GLP1 agonist drugs on cardiovascular disease in diabetes
   Garg, Vinay, Verma, Subodh, Connelly, Kim · 2019 · Progress in Cardiovascular Diseases
6. Cardiovascular disease prevalence and risk factor prevalence in Type 2 diabetes: a contemporary analysis
   Stuart J. McGurnaghan, Luke A. K. Blackbourn, Emina Mocevic, Ulrik Haagen Panton, Rory J. McCrimmon, Naveed A. Sattar, Sarah H. Wild, Helen Martina Colhoun · 2018 · Diabetic Medicine
7. Cardiovascular outcome trials of glucose-lowering medications: an update
   Philip D. Home · 2019 · Diabetologia
8. Cardiovascular outcomes of type 2 diabetic patients treated with SGLT-2 inhibitors versus GLP-1 receptor agonists in real-life
   Enrico Longato, Barbara Di Camillo, Giovanni Sparacino, Lorenzo Gubian, Angelo Avogaro, Gian Paolo Fadini · 2020 · BMJ Open Diabetes Research & Care
9. GLP-1 receptor agonists in the treatment of type 2 diabetes: role and clinical experience to date
   Stephen Brunton, Carol Wysham · 2020 · Postgraduate Medicine
10. Liraglutide dictates macrophage phenotype in apolipoprotein E null mice during early atherosclerosis
    Robyn Bruen, Seán Curley, Sarina Kajani, Daniel Crean, Marcella E. O'Reilly, Margaret B. Lucitt, Catherine Godson, Fiona C. McGillicuddy, Orina Belton · 2017 · Cardiovascular Diabetology
11. Barriers to prescribing glucose-lowering therapies with cardiometabolic benefits
    Yumin Gao, Eric David Peterson, Neha Jadeja Pagidipati · 2020 · American Heart Journal
12. Advances in the management of chronic kidney disease
    Teresa K. Chen, Melanie P. Hoenig, Dorothea Nitsch, Morgan Erika Grams · 2023 · BMJ
13. Microvascular effects of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled trials
    Ilaria Dicembrini, Besmir Nreu, Alessia Scatena, Francesco Andreozzi, Giorgio Sesti, Edoardo Mannucci, Matteo Monami · 2017 · Acta Diabetologica
14. Diabetes-related cardiomyopathy: the sweet story of glucose overload from epidemiology to cellular pathways
    Joubert, M., Manrique, A., Cariou, B., Prieur, X. · 2019 · Diabetes & Metabolism
15. Oral semaglutide in type 2 diabetes
    Sarah L. Anderson, Trevor R. Beutel, Jennifer M. Trujillo · 2020 · Journal of Diabetes and its Complications
16. Effect of treatment with exenatide and pioglitazone or basal-bolus insulin on diabetic neuropathy: a substudy of the Qatar Study
    Georgios Ponirakis, Muhammad A Abdul‐Ghani, Amin Jayyousi, Hamad Almuhannadi, Ioannis Nikolaos Petropoulos, Adnan Khan, Hoda Gad, Osama Migahid, Ayman Megahed, Ralph Anthony DeFronzo et al. · 2020 · BMJ Open Diabetes Research & Care
17. An update on DPP-4 inhibitors in the management of type 2 diabetes
    Avivit Cahn, Simona Cernea, Itamar Raz · 2016 · Expert Opinion on Emerging Drugs
18. Comparisons of diabetic retinopathy events associated with glucose‐lowering drugs in patients with type 2 diabetes mellitus: A network meta‐analysis
    Huilin Tang, Guangyao Li, Ying Jiao Zhao, Fei Wang, Emily West Gower, Luwen Shi, Tiansheng Wang · 2018 · Diabetes Obesity and Metabolism
19. The Ascending GLP-1 Road From Clinical Safety to Reduction of Cardiovascular Complications
    Daniel J. Drucker · 2018 · Diabetes
20. What Is an L-Cell and How Do We Study the Secretory Mechanisms of the L-Cell?
    Rune E. Kuhre, Carolyn Fiona Deacon, Jens Juul Holst, Natalia Petersen · 2021 · Frontiers in Endocrinology
21. Incorporating SGLT2i and GLP-1RA for Cardiovascular and Kidney Disease Risk Reduction: Call for Action to the Cardiology Community
    Adam J. Nelson, Neha Jadeja Pagidipati, Vanita R. Aroda, Matthew Aaron Cavender, Jennifer B. Green, Renato D. Lópes, Hussein R. Al‐Khalidi, Tanya Gaynor, Lisa A. Kaltenbach, Julienne K. Kirk et al. · 2021 · Circulation
22. Cardiovascular benefits of GLP-1 agonists in type 2 diabetes: a comparative review
    James G. Boyle, Rachel Livingstone, John R. Petrie · 2018 · Clinical Science
23. Therapeutic medications against diabetes: What we have and what we expect
    Cheng Hu, Weiping Jia · 2018 · Advanced Drug Delivery Reviews
24. Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes
    Zeqing Zhang, Xi Chen, Puhan Lu, Jianhua Zhang, Yongping Xu, Wentao He, Mengni Li, Shujun Zhang, Jing Jia, Shiying Shao et al. · 2017 · Cardiovascular Diabetology
25. Cardioprotective GLP-1 metabolite prevents ischemic cardiac injury by inhibiting mitochondrial trifunctional protein-α
    M. Ahsan Siraj, Dhanwantee Mundil, Sanja Beca, Abdul Momen, Eric A. Shikatani, Talat Afroze, Xuetao Sun, Ying Liu, Siavash Ghaffari, Warren L. Lee et al. · 2020 · Journal of Clinical Investigation
26. A review of practical issues on the use of glucagon-like peptide-1 receptor agonists for the management of type 2 diabetes
    Romera, Irene, Cebrián-Cuenca, Ana, Álvarez-Guisasola, Fernando, Gomez-Peralta, Fernando, Reviriego, Jesús · 2019 · Diabetes Therapy
27. Cardiovascular Disease in Type 2 Diabetes: A Review of Sex-Related Differences in Predisposition and Prevention
    Al-Salameh, Abdallah, Chanson, Philippe, Bucher, Sophie, Ringa, Virginie, Becquemont, Laurent · 2019 · Mayo Clinic Proceedings
28. Heart Failure With Preserved Ejection Fraction in Diabetes: Mechanisms and Management
    Patrick Meagher, Mohamed Adam, Robert Civitarese, Antoinette Bugyei‐Twum, Kim Alexander Connelly · 2018 · Canadian Journal of Cardiology
29. Predicting and preventing heart failure in type 2 diabetes
    Ambarish Pandey, Muhammad Shahzeb Khan, Kershaw V. Patel, Deepak L. Bhatt, Subodh Verma · 2023 · The Lancet Diabetes & Endocrinology
30. Concurrent diabetes and heart failure: interplay and novel therapeutic approaches
    Qutuba G. Karwi, Kim L. Ho, Simran Pherwani, Ezra B. Ketema, Qiuyu Sun, Gary D. Lopaschuk · 2021 · Cardiovascular Research
31. Liraglutide improves cardiac function in patients with type 2 diabetes and chronic heart failure
    Franco Arturi, Elena Succurro, Sofia Miceli, Cosima Cloro, Mariafrancesca Ruffo, Raffaele Maio, Maria Perticone, Giorgio Sesti, Francesco Perticone · 2016 · Endocrine
32. Endogenous Activation of Glucagon-Like Peptide-1 Receptor Contributes to Blood Pressure Control
    Flavia L. Martins, Matthew A. Bailey, Adriana C. C. Girardi · 2020 · Hypertension
33. GLP-1 receptor agonists’ impact on cardio-renal outcomes and mortality in T2D with acute kidney disease
    Pan, Heng-Chih, Chen, Jui-Yi, Chen, Hsing-Yu, Yeh, Fang-Yu, Sun, Chiao-Yin, Huang, Thomas Tao-Min, Wu, Vin-Cent · 2024 · Nature Communications
34. Switching Between Glucagon-Like Peptide-1 Receptor Agonists: Rationale and Practical Guidance
    Almandoz, Jaime P., Lingvay, Ildiko, Morales, Javier, Campos, Carlos · 2020 · Clinical Diabetes
35. Current perspectives on cardiovascular outcome trials in diabetes
    on behalf of the D&CVD EASD Study Group, Oliver Schnell, Lars Rydén, Eberhard Standl, Antonio Ceriello · 2016 · Cardiovascular Diabetology
36. Heart failure in the patient with diabetes: Epidemiology, aetiology, prognosis, therapy and the effect of glucose‐lowering medications
    David S.H. Bell, Edison Gonçalves · 2019 · Diabetes Obesity and Metabolism
37. Diabetes and kidney disease: emphasis on treatment with SGLT-2 inhibitors and GLP-1 receptor agonists
    Francesco Prattichizzo, Paola de Candia, Antonio Ceriello · 2021 · Metabolism
38. Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND
    Konig, Manige, Riddle, Matthew C., Colhoun, Helen M., Branch, Kelley R., Atisso, Charles M., Lakshmanan, Mark C., Mody, Reema, Raha, Sohini, Gerstein, Hertzel C. · 2021 · Cardiovascular Diabetology
39. Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes
    Melanie Jane Davies, Heinz Drexel, François R. Jornayvaz, Zoltan Pataky, Petar M Seferovic, Christoph Wanner · 2022 · Cardiovascular Diabetology
40. Improvement of glycemic control and reduction of major cardiovascular events in 18 cardiovascular outcome trials: an updated meta-regression
    Maiorino, Maria Ida, Longo, Miriam, Scappaticcio, Lorenzo, Bellastella, Giuseppe, Chiodini, Paolo, Esposito, Katherine, Giugliano, Dario · 2021 · Cardiovascular Diabetology
41. Therapeutic Considerations for Antihyperglycemic Agents in Diabetic Kidney Disease
    Joshua J. Neumiller, Radica Z. Alicic, Katherine R. Tuttle · 2017 · Journal of the American Society of Nephrology
42. Composite Primary End Points in Cardiovascular Outcomes Trials Involving Type 2 Diabetes Patients: Should Unstable Angina Be Included in the Primary End Point?
    Nikolaus Marx, Darren K. McGuire, Vlado Perkovic, Hans‐Juergen Woerle, Uli C. Broedl, Maximilian von Eynatten, Jyothis Thomas George, Julio Rosenstock · 2017 · Diabetes Care
43. Cardiovascular Disease and Diabetic Kidney Disease
    Muhammad Maqbool, Mark Emmanuel Cooper, Karin Agnes Maria Jandeleit-Dahm · 2018 · Seminars in Nephrology
44. The blood pressure lowering effects of glucagon-like peptide-1 receptor agonists: a mini-review of the potential mechanisms
    Ribeiro-Silva, Joao Carlos, Tavares, Caio A.M., Girardi, Adriana C.C. · 2023 · Current Opinion in Pharmacology
45. How glucagon-like peptide 1 receptor agonists work
    Andreasen, Christine Rode, Andersen, Andreas, Knop, Filip Krag, Vilsbøll, Tina · 2021 · Endocrine Connections
46. Cardiovascular Protection in People With Diabetes
    James A. Stone, Robyn L. Houlden, Peter Lin, Jacob Allen Udell, Subodh Verma · 2018 · Canadian Journal of Diabetes
47. Use of liraglutide and risk of major cardiovascular events: a register-based cohort study in Denmark and Sweden
    Henrik Svanström, Peter Ueda, Mads Melbye, Björn Eliasson, Ann‐Marie Svensson, Stefan Franzén, Soffia Guðbjörnsdóttir, Kristian Hveem, Christian Jonasson, Björn Pasternak · 2018 · The Lancet Diabetes & Endocrinology
48. From glucose lowering agents to disease/diabetes modifying drugs: a “SIMPLE” approach for the treatment of type 2 diabetes
    Ofri Mosenzon, Stefano Del Prato, Meir Schechter, Lawrence A. Leiter, Antonio Ceriello, Ralph Anthony DeFronzo, Itamar Raz · 2021 · Cardiovascular Diabetology
49. Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis
    Kanie, T, Mizuno, A, Takaoka, Y, Suzuki, T, Yoneoka, D, Nishikawa, Y, Tam, WWS, Morze, J, Rynkiewicz, A, Xin, Y et al. · 2021 · UCL Discovery (University College London)
50. Insulin Resistance, Obesity, and Lipotoxicity
    Dilek Yazıcı, Selin Çakmak Demir, Havva Sezer · 2024 · Advances in experimental medicine and biology
51. Cardiorenal Protection: Potential of SGLT2 Inhibitors and GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes
    Taichi Nagahisa, Yoshifumi Saisho · 2019 · Diabetes Therapy
52. Glucagon-like peptide 1 receptor agonists and the risk of incident diabetic retinopathy
    Douros, Antonios, Filion, Kristian B., Yin, Hui, Yu, Oriana Hoi, Etminan, Mahyar, Udell, Jacob A., Azoulay, Laurent · 2018 · Diabetes Care
53. New Diabetes Therapies and Diabetic Kidney Disease Progression: the Role of SGLT-2 Inhibitors
    Claire C. J. Dekkers, Ron T. Gansevoort, Hiddo J.L. Heerspink · 2018 · Current Diabetes Reports
54. Meta-analyses of Results From Randomized Outcome Trials Comparing Cardiovascular Effects of SGLT2is and GLP-1RAs in Asian Versus White Patients With and Without Type 2 Diabetes
    Matthew M.Y. Lee, Nazim Ghouri, Darren K. McGuire, Martin K. Rutter, Naveed A. Sattar · 2021 · Diabetes Care
55. Effects of GLP-1 receptor agonists and SGLT-2 inhibitors on cardiac structure and function: a narrative review of clinical evidence
    Andrea Natali, Lorenzo Nesti, Domenico Tricò, Ele Ferrannini · 2021 · Cardiovascular Diabetology
56. Incretin based treatments and mortality in patients with type 2 diabetes: systematic review and meta-analysis
    Jiali Liu, Ling Li, Ke Deng, Chang Xu, Jason Walter Busse, Per Olav Vandvik, Sheyu Li, Gordon Henry Guyatt, Xin Sun · 2017 · BMJ
57. Effects of liraglutide compared with placebo on events of acute gallbladder or biliary disease in patients with type 2 diabetes at high risk for cardiovascular events in the LEADER randomized trial.
    Nauck, Michael A., Muus Ghorbani, Marie Louise, Kreiner, Eskil, Saevereid, Hans A., Buse, John B., the LEADER Publication Committee on behalf of the LEADER Trial Investigators · 2019 · Diabetes Care
58. SGLT2 inhibitors: are they safe?
    Sempastian Filippas-Ntekouan, Theodosios D. Filippatos, Moses Elisaf · 2017 · Postgraduate Medicine
59. Major adverse cardiovascular and limb events in patients with diabetes treated with GLP-1 receptor agonists vs DPP-4 inhibitors
    Lin, Donna Shu-Han, Lee, Jen-Kuang, Chen, Wen-Jone · 2021 · Diabetologia
60. GLP-1 agonist to treat obesity and prevent cardiovascular disease: what have we achieved so far
    Pedrosa, Maurício Reis, Franco, Denise Reis, Gieremek, Hannah Waisberg, Vidal, Camila Maia, Bronzeri, Fernanda, de Cassia Rocha, Alexia, de Carvalho Cara, Luis Gabriel, Fogo, Sofia Lenzi, Eliaschewitz, Freddy Goldberg · 2022 · Current Atherosclerosis Reports
61. Integration of recent evidence into management of patients with atherosclerotic cardiovascular disease and type 2 diabetes
    Eberhard Standl, Oliver Schnell, Darren K. McGuire, Antonio Ceriello, Lars Rydén · 2017 · The Lancet Diabetes & Endocrinology
62. Glucose-lowering therapies in patients with type 2 diabetes and cardiovascular diseases
    Francesco Prattichizzo, Lucia La Sala, Lars Rydén, Nikolaus Marx, Marc Ferrini, Paul Elie Valensi, Antonio Ceriello · 2019 · European Journal of Preventive Cardiology
63. Preoperative considerations of new long-acting glucagon-like peptide-1 receptor agonists in diabetes mellitus
    Abraham Hendrikus Hulst, Jorinde A. W. Polderman, Sarah E. Siegelaar, Daniël H. van Raalte, J. Hans DeVries, Benedikt Preckel, Jeroen Hermanides · 2020 · British Journal of Anaesthesia
64. Incretin Hormones in Obesity and Related Cardiometabolic Disorders: The Clinical Perspective
    Joanna Michałowska, Ewa Miller‐Kasprzak, Paweł Bogdański · 2021 · Nutrients
65. Glucagon-like peptide-1 receptor agonists and atrial fibrillation: a systematic review and meta-analysis of randomised controlled trials
    Matteo Monami, Besmir Nreu, Alessia Scatena, Stefano Giannini, Francesco Andreozzi, Giorgio Sesti, Edoardo Mannucci · 2017 · Journal of Endocrinological Investigation
66. Glucagon-like Peptide-1 Receptor Agonists and Cardiovascular Events: Class Effects versus Individual Patterns
    Soo Kyung Lim, Kyoung Min Kim, Michael Albrecht Nauck · 2018 · Trends in Endocrinology and Metabolism
67. GLP ‐1 receptor agonists and the risk for cancer: A meta‐analysis of randomized controlled trials
    Silverii, Giovanni Antonio, Marinelli, Christian, Bettarini, Costanza, Del Vescovo, Gloria Giovanna, Monami, Matteo, Mannucci, Edoardo · 2025 · Diabetes, Obesity and Metabolism
68. Cardiovascular protective properties of GLP-1 receptor agonists: more than just diabetic and weight loss drugs
    Le, Richard, Nguyen, Mau T., Allahwala, Momina A., Psaltis, James P., Marathe, Chinmay S., Marathe, Jessica A., Psaltis, Peter J. · 2024 · Journal of Clinical Medicine
69. Glucagon-like Peptide-1 Receptor Agonists: A Class Update for Treating Type 2 Diabetes
    Julie A. Lovshin · 2017 · Canadian Journal of Diabetes
70. Common medications used by patients with type 2 diabetes mellitus: what are their effects on the lipid profile?
    Paul D. Rosenblit · 2016 · Cardiovascular Diabetology
71. Prevention of cardiovascular disease through reduction of glycaemic exposure in type 2 diabetes: A perspective on glucose‐lowering interventions
    Ronan Roussel, Philippe Gabríel Steg, Kamel Mohammedi, Michel Marre, Louis Potier · 2017 · Diabetes Obesity and Metabolism
72. Recent advances in understanding the role of glucagon-like peptide 1
    Reed, Josh, Bain, Stephen, Kanamarlapudi, Venkateswarlu · 2020 · F1000Research
73. Glucagon-like peptide 1 receptor agonists in patients with type 2 diabetes with and without chronic heart failure: a meta-analysis of randomized placebo-controlled outcome trials
    Ferreira, João Pedro, Saraiva, Francisca, Sharma, Abhinav, Vasques‐Nóvoa, Francisco, Angélico‐Gonçalves, António, Leite, Ana Rita, Borges‐Canha, Marta, Carvalho, Davide, Packer, Milton, Zannad, Faiez et al. · 2023 · Diabetes, Obesity and Metabolism
74. The prevalence of cardiovascular disease and antidiabetes treatment characteristics among a large type 2 diabetes population in the United States.
    Weng, Wayne, Tian, Ye, Kong, Sheldon X., Ganguly, Rahul, Hersloev, Malene, Brett, Jason, Hobbs, Todd · 2019 · Endocrinology, Diabetes & Metabolism
75. GLP-1 receptor agonists and heart failure in diabetes
    André Jacques Scheen · 2017 · Diabetes & Metabolism
76. Consensus recommendations for management of patients with type 2 diabetes mellitus and cardiovascular diseases
    Alaaeldin M. Bashier, Azza Khalifa Bin Hussain, Elamin Abdelgadir, Fatheya Alawadi, Hani Mohamed Sabbour, ROBERT J. CHILTON · 2019 · Diabetology & Metabolic Syndrome
77. GLP-1 receptor agonists in diabetes for stroke prevention: a systematic review and meta-analysis
    Malhotra, Konark, Katsanos, Aristeidis H., Lambadiari, Vaia, Goyal, Nitin, Palaiodimou, Lina, Kosmidou, Maria, Krogias, Christos, Alexandrov, Andrei V., Tsivgoulis, Georgios · 2020 · Journal of Neurology
78. Progression of retinopathy with glucagon-like peptide-1 receptor agonists with cardiovascular benefits in type 2 diabetes – A systematic review and meta-analysis
    Yoshida, Yilin, Joshi, Preeti, Barri, Saba, Wang, Jia, Corder, Amy L., O'Connell, Samantha S., Fonseca, Vivian A. · 2022 · Journal of Diabetes and its Complications
79. Vascular Biology of Glucagon Receptor Superfamily Peptides: Mechanistic and Clinical Relevance
    Gemma Pujadas, Daniel J. Drucker · 2016 · Endocrine Reviews
80. SGLT2 inhibitors: the future for treatment of type 2 diabetes mellitus and other chronic diseases
    Wanner, Christoph, Marx, Nikolaus · 2018 · Diabetologia
81. Mechanisms by Which Glucagon-Like-Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors Reduce Cardiovascular Risk in Adults With Type 2 Diabetes Mellitus
    Abhinav Sharma, Subodh Verma · 2019 · Canadian Journal of Diabetes
82. DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases
    Handelsman, Yehuda, Anderson, John E., Bakris, George L., Ballantyne, Christie M., Beckman, Joshua A., Bhatt, Deepak L., Bloomgarden, Zachary T., Bozkurt, Biykem, Budoff, Matthew J., Butler, Javed et al. · 2022 · Journal of Diabetes and its Complications
83. Renal Outcomes in Type 2 Diabetes: A Review of Cardiovascular and Renal Outcome Trials
    David M. Williams, Asif Nawaz, Marc Evans · 2019 · Diabetes Therapy
84. Preventing Heart Failure: A Position Paper of the Heart Failure Association in Collaboration with the European Association of Preventive Cardiology
    Massimo Francesco Piepoli, Marianna Adamo, Andrea Barison, Reinaldo B. Bestetti, Jan Biegus, Michael Böhm, Javed Butler, Jonathan Rhys Carapetis, Claudio Ceconi, Ovidiu Dragomir Chioncel et al. · 2022 · European Journal of Heart Failure
85. Diabetic Cardiomyopathy: A Brief Summary on Lipid Toxicity
    Jiahan Ke, Jianan Pan, Hao Lin, Jun Gu · 2022 · ESC Heart Failure
86. Cardiovascular Mortality in Patients With Type 2 Diabetes and Recent Acute Coronary Syndromes From the EXAMINE Trial
    William B. White, Stuart Kupfer, Faiez M. Zannad, C R Mehta, Craig Wilson, Lanyu Lei, George L. Bakris, Steven E. Nissen, William C. Cushman, Simon R. Heller et al. · 2016 · Diabetes Care
87. Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)
    Robert John Mentz, Mary Angelyn Bethel, Stephanie M. Gustavson, Vivian P. Thompson, Neha Jadeja Pagidipati, John B. Buse, Juliana C.N. Chan, Nayyar Iqbal, Aldo Pietro Maggioni, Steve P. Marso et al. · 2017 · American Heart Journal
88. Is It Time to Change the Type 2 Diabetes Treatment Paradigm? Yes! GLP-1 RAs Should Replace Metformin in the Type 2 Diabetes Algorithm
    Muhammad A. Abdul-Ghani, Ralph Anthony DeFronzo · 2017 · Diabetes Care
89. Clinical pharmacology of glucagon-like peptide-1 receptor agonists
    Dimitrios G. Sfairopoulos, Stavros Liatis, Stelios K. Tigas, Evangelos N. Liberopoulos · 2018 · HORMONES
90. More Than 7 Years of Hindsight: Revisiting the FDA’s 2008 Guidance on Cardiovascular Outcomes Trials for Type 2 Diabetes Medications
    Emily E. Regier, Manu V. Venkat, Kelly L. Close · 2016 · Clinical Diabetes
91. Pancreatitis and pancreatic cancer in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonists: an updated meta-analysis of randomized controlled trials
    NREU, Besmir, DICEMBRINI, Ilaria, TINTI, Federico, MANNUCCI, Edoardo, MONAMI, Matteo · 2023 · Minerva Endocrinology
92. Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Systematic Review and Network Meta-analysis for the American College of Physicians
    Tyler C. Drake, Adrienne M. K. Landsteiner, Lisa Langsetmo, Roderick H. MacDonald, Maylen Anthony, Caleb Kalinowski, Kristen E. Ullman, Charles John Billington, Anjum S. Kaka, Shahnaz Sultan et al. · 2024 · Annals of Internal Medicine
93. Improving glycaemic control in type 2 diabetes: S timulate insulin secretion or provide beta‐cell rest?
    Daniël H. van Raalte, C. Bruce Verchere · 2017 · Diabetes Obesity and Metabolism
94. Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study
    Devin Abrahami, Antonios Douros, Hui Yin, Oriana HY Yu, Jean‐Luc Faillie, François Montastruc, Robert William Platt, Nathaniel Bouganim, Laurent Azoulay · 2018 · BMJ
95. Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials
    Kaul, Sanjay · 2017 · Diabetes Care
96. Glucagon‐like peptide‐1 receptor agonists and cardiovascular outcomes in patients with and without prior cardiovascular events: An updated meta‐analysis and subgroup analysis of randomized controlled trials
    Edoardo Mannucci, Ilaria Dicembrini, Besmir Nreu, Matteo Monami · 2019 · Diabetes Obesity and Metabolism
97. Rationale for Timely Insulin Therapy in Type 2 Diabetes Within the Framework of Individualised Treatment: 2020 Update
    M Hanefeld, Holger Fleischmann, Thorsten Siegmund, Jochen Seufert · 2020 · Diabetes Therapy
98. Glucagon-like Peptide-1 Receptor Agonists in the Management of Type 2 Diabetes Mellitus and Obesity: The Impact of Pharmacological Properties and Genetic Factors
    Jasna Klen, Vita Dolžan · 2022 · International Journal of Molecular Sciences
99. Postprandial renal haemodynamic effect of lixisenatide vs once‐daily insulin‐glulisine in patients with type 2 diabetes on insulin‐glargine: An 8‐week, randomised, open‐label trial
    Tonneijck, Lennart, Muskiet, Marcel H. A., Smits, Mark M., Hoekstra, Trynke, Kramer, Mark H. H., Danser, A. H. Jan, Diamant, Michaela, Joles, Jaap A., van Raalte, Daniël H. · 2017 · Diabetes, Obesity and Metabolism
100. Lixisenatide in Type 2 Diabetes and Acute Coronary Syndrome
     Marc A Pfeffer, Brian Lee Claggett, Jeffrey L Probstfield · 2016 · New England Journal of Medicine